Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.53 |
| ▸ | FLT1 | P17948 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.51 |
| ▸ | CSF1R | P07333 | 9/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.50 |
| ▸ | KIT | P10721 | 5/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.50 |
| ▸ | MET | P08581 | 3/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5435810 | 0.95 | KDR (0.50) | KDRFLT1AURKAAURKBCSF1R | |
| SCHEMBL5441045 | 0.94 | KDR (0.55) | KDRFLT1AURKAAURKBCSF1R | |
| SCHEMBL5434653 | 0.94 | KDR (0.51) | KDRFLT1AURKAAURKBCSF1R | |
| SCHEMBL5445707 | 0.92 | GRM5 (0.52) | KDRFLT1CSF1RPDGFRBKIT | |
| SCHEMBL5449985 | 0.92 | KDR (0.51) | KDRFLT1AURKAAURKBCSF1R | |
| SCHEMBL5434836 | 0.92 | AURKB (0.61) | KDRFLT1AURKAAURKBCSF1R | |
| SCHEMBL5432770 | 0.91 | AURKB (0.55) | KDRFLT1AURKAAURKBCSF1R | |
| SCHEMBL5436669 | 0.90 | AURKA (0.52) | KDRFLT1AURKAAURKBCSF1R | |
| SCHEMBL5443638 | 0.88 | KMT2A (0.54) | KDRFLT1CSF1RPDGFRBPDGFRA | |
| SCHEMBL5441856 | 0.87 | KDR (0.50) | KDRFLT1AURKAAURKBCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155746-A1 | NOVEL SUBSTITUTED PYRIDINYLOXY AND PYRIMIDINYLOXY AMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155746-A1 | NOVEL SUBSTITUTED PYRIDINYLOXY AND PYRIMIDINYLOXY AMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155746-A1 | NOVEL SUBSTITUTED PYRIDINYLOXY AND PYRIMIDINYLOXY AMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155746-A1 | NOVEL SUBSTITUTED PYRIDINYLOXY AND PYRIMIDINYLOXY AMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | BRAF, ARAF, RAF1 | KDR 508/4885FLT1 423/4885AURKA 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.